InnoCare Pharma (HKSE:09969) Net Issuance of Preferred Stock : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

InnoCare Pharma's net issuance of preferred for the three months ended in Dec. 2023 was HK$0.0 Mil. The number is 0, which means that InnoCare Pharma has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

InnoCare Pharma's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.0 Mil.

InnoCare Pharma Net Issuance of Preferred Stock Historical Data

The historical data trend for InnoCare Pharma's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Net Issuance of Preferred Stock Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

459.20

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial											-	-	-	-	-

InnoCare Pharma Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

InnoCare Pharma Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines